Grape King Bio (1707 TT): Botanical new drug USFDA IND applied

USFDA Botanical Drug Application:

We have announced that our new botanical drug “GKAC”, which has been independently developed by our Grape King Biotech Research Institute, has applied to the US Food and Drug Administration (USFDA) for a Phase II clinical trial review (IND) for nonalcoholic steatohepatitis in humans. If approved, we will conduct Phase II clinical trials. After successful completion, it will become Grape King Bio’s first new botanical drug that has stepped out of the field of health food and expand our expertise. “GKAC” (based on Antrodia camphorata mycelium) is a 100% exclusive material of Grape King Biotechnology. Key components were found in clinical pre-experiments, which can significantly improve liver function in patients with non-alcoholic fatty liver disease (NAFLD). Non-alcoholic fatty liver disease is the number one liver disease in the world today. This disease is the initial stage of the development of liver disease such as steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma (i.e. liver cancer). If our botanical is drug is passed by USFDA, it will be the first drug of its kind to treat non-alcoholic fatty liver disease (NAFLD).